Use of Atezolizumab and Bevacizumab to Treat Advanced HCC
In recent years, significant progress has been made in treating advanced unresectable...
Read More
Dissemination (Meeting Coverage)
Utilizing Genomic Features and Protein Markers for MRD Detection in HCC Patients
Many researchers determined that the clinical significance of circulating tumor DNA (ctDNA) in...
Read More
Impacting OS in Patients with Unresectable HCC with 1L TIS
Tislelizumab (TIS) is a specific monoclonal antibody targeting programmed cell death protein 1...
Read More
Adjuvant Atezolizumab Impact on Recurrence Prevention and Cost Reduction in Early PD-L1 High NSCLC
Recurrent cases of non-small cell lung cancer (NSCLC) following surgery are common and carry...
Read More
Race and Curative-Intent Treatment Linked To Mortality Outcomes in Early-Stage NSCLC
In recent decades, persistent disparities in the survival of individuals with early-stage...
Read More
New Blood-Based RNA Platform for Early Lung Cancer Diagnosis
Blood-based methods utilizing circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) are...
Read More
CtDNA as Outcome Predictor in NSCLC Undergoing Targeted Therapies: A Meta-Analysis
For treating non-small cell lung cancer (NSCLC), liquid biopsy (LB) was analyzed using...
Read More
Adjuvant Chemotherapy in High-Risk, Early-Stage NSCLC with Clinical and Pathologic Features Reevaluated
Surgical resection is the preferred treatment for early-stage non-small cell lung cancer (NSCLC),...
Read More
FOF and Concern of Falling in Patients with Relapsing-Remitting or Progressive MS
Frequent falls and the fear of falling (FOF) are significant challenges experienced by individuals...
Read More
Mindfulness-Based Stress Reduction in MS: Correlates of Patient-Reported Outcomes and MRI Findings
Researchers conducted a study to examine the effects of mindfulness-based stress reduction (MBSR)...
Read More
Low-Fat Diet Trial: Assessing Fatigue in Multiple Sclerosis
Fatigue is a common and debilitating symptom among individuals with multiple sclerosis (MS)....
Read More
Pharmacological Comparison of Tolebrutinib with Other BTK Inhibitor Candidates for MS Treatment
Tolebrutinib, a covalent inhibitor of Bruton tyrosine kinase (BTK), has been specifically...
Read More
MRI Results of Tolebrutinib Long-Term Safety Extension Study in Relapsing MS
Tolebrutinib, a potent inhibitor of Bruton tyrosine kinase that can cross the blood-brain barrier,...
Read More
MS Therapies Not Associated With Pregnancy Complications
A registry data analysis concluded that most disease-modifying therapies for MS are not associated...
Read More
Q&A: Can Remyelination of Axons Restore Vision in MS?
The VISIONARY-MS trial showed that CNM-Au8, an oral liquid suspension of gold nanoparticles,...
Read More
Orphan Non-Coding RNAs Have Potential for Early Identification of NSCLC
Orphan non-coding RNAs demonstrated efficacy for accurate, sensitive, and early detection of...
Read More
SphK2 Shows Promise for Overcoming NSCLC Tumor Progression
Sphingosine kinase 2 may be a promising clinical target for overcoming EGFR-TKI resistance and...
Read More
Stem Cell Therapy Improves Walking in More Advanced Progressive MS
Intrathecal mesenchymal stem cell-neural progenitor therapy failed to significantly improve the...
Read More
Gold Nanocrystals May Be Effective as Adjunctive MS Therapy
The VISIONARY-MS study suggests catalytically active gold nanocrystals given in addition to...
Read More
Teriflunomide Prevents Conversion to MS in Patients With RIS
In people with radiologically isolated syndrome, teriflunomide resulted in a 62% risk decline for...
Read More